
Loading, please wait...

Loading, please wait...

Managing smoking cessation mental illness remains a significant challenge for healthcare providers globally. The KISMET cluster-randomized trial, recently conducted in the Netherlands, evaluated a specialized intervention for individuals with severe mental illness (SMI). This one-year study aimed to bridge the gap between psychiatric care and physical health by offering a structured quitting program within outpatient mental healthcare teams. Consequently, researchers focused on long-term abstinence rather than short-term success alone.
The study highlights that specialized programs can effectively support smoking cessation mental illness goals. Eleven teams delivered the KISMET intervention, while ten provided treatment as usual. Specifically, the intervention combined cognitive-behavioral therapy and peer support with optional pharmacological treatments. The results showed significantly higher cessation rates in the intervention group at three months and twelve months. However, the differences were not statistically significant at the six-month mark. Therefore, the timing of support may be crucial for maintaining motivation.
Clinicians often worry about the psychiatric stability of patients during quit attempts. Fortunately, this trial found no significant physical or psychopathological complications associated with the intervention. Secondary outcomes, including depression, anxiety, and psychotic symptom severity, remained stable across both groups. Additionally, physical parameters like blood pressure and body mass index showed no detrimental changes. Nevertheless, the high dropout rate of 58% in the intervention group suggests that maintaining long-term engagement is difficult. This high attrition rate indicates that future programs might require more personalized approaches.
The KISMET intervention demonstrates significant potential for integrating lifestyle changes into standard psychiatric care. While the quit rates are promising, the high attrition highlights a need for more resilient support systems. Moreover, the integration of peer support and pharmacotherapy appears to be a safe and effective pathway for this vulnerable population. Providers should consider these findings when designing tobacco cessation protocols for patients with severe mental disorders.
The intervention includes cognitive-behavioral therapy, peer support groups led by experts-by-experience, and optional pharmacological treatment, such as nicotine replacement therapy or other cessation medications.
Yes, the KISMET trial and broader literature indicate that smoking cessation does not worsen psychiatric symptoms when managed correctly by clinical teams within a mental health setting.
Severe mental illness often involves cognitive and motivational challenges. Consequently, participants may find long-term, intensive behavioral programs difficult to complete without extensive individual tailoring and consistent encouragement.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
1. K眉莽眉kaksu M et al. Effectiveness of a one-year smoking cessation intervention for people with severe mental illness: results of the KISMET cluster-randomized controlled trial. Psychol Med. 2026 May 15. doi: 10.1017/S0033291726104516. PMID: 42138038.
2. Ministry of Health and Family Welfare, Government of India. Tobacco Dependence Treatment Guidelines.
3. World Health Organization. WHO treatment recommendations for tobacco cessation in people with severe mental illness.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


The KISMET trial evaluates a smoking cessation intervention for severe mental illness, showing significant quit rates at 12 months despite high dropout rate...
3 months ago

Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today

A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today

Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today

Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday

The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today